Related Experiment Video

Updated: Jun 25, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment

Jaume Capdevila1, Elena Elez, Teresa Macarulla

  • 1Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. jacapdevila@vhebron.net

Cancer Treatment Reviews
|March 10, 2009
PubMed

Insights

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) pathway represent a significant advancement in cancer therapy. These targeted therapies impact cell cycle and show promise in various tumor types.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cancer prognosis remains poor despite advances in diagnostics and treatment.
  • Understanding molecular pathways like epidermal growth factor receptor (EGFR) signaling offers novel therapeutic targets.
  • EGFR signaling is crucial in cell growth, apoptosis, angiogenesis, and invasion.

Purpose of the Study:

  • To review the development of monoclonal antibodies targeting EGFR.
  • To examine the effects of EGFR pathway blockade on the cell cycle.
  • To discuss clinical trials of EGFR-targeted monoclonal antibodies in various cancers.

Main Methods:

  • Review of scientific literature on EGFR-targeted monoclonal antibodies.
  • Analysis of studies investigating EGFR pathway inhibition.
  • Examination of clinical trial data for efficacy and impact on tumor types.

Main Results:

  • Monoclonal antibodies against EGFR have been developed as targeted therapies.
  • EGFR pathway blockade affects critical cellular processes, including the cell cycle.
  • Clinical trials demonstrate the utility of these antibodies across diverse tumor types.

Conclusions:

  • Monoclonal antibodies targeting EGFR are a valuable addition to cancer treatment strategies.
  • Further research and clinical application of these therapies are warranted.
  • Targeting molecular pathways like EGFR offers personalized treatment approaches for cancer patients.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...